Research Analysts Issue Forecasts for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biotechnology company will post earnings per share of ($0.27) for the year. Cantor Fitzgerald has a "Overweight" rating and a $20.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

Several other research firms have also issued reports on BCRX. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Needham & Company LLC reissued a "buy" rating and set a $15.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 10th. Wedbush began coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price target on the stock. Royal Bank of Canada reissued an "outperform" rating and issued a $11.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. Finally, Evercore ISI lifted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $16.13.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock traded up $2.10 during midday trading on Thursday, hitting $11.03. 24,785,100 shares of the stock were exchanged, compared to its average volume of 2,916,218. BioCryst Pharmaceuticals has a 1 year low of $4.75 and a 1 year high of $11.48. The company has a 50 day moving average price of $7.69 and a two-hundred day moving average price of $7.80. The firm has a market cap of $2.31 billion, a P/E ratio of -18.08 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.27. During the same period in the previous year, the business posted ($0.17) EPS. The company's quarterly revenue was up 56.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $33,000. GAMMA Investing LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth $46,000. R Squared Ltd bought a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $48,000. Finally, KBC Group NV raised its holdings in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 4,537 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.